Locus Coeruleus-Hippocampal Circuit Protection

Target: MAPT Composite Score: 0.668 Price: $0.63▲29.2% Citation Quality: Pending neuroscience Status: promoted

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🔴 Alzheimer's Disease 🧠 Neurodegeneration 🔥 Neuroinflammation

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

Composite: 0.668

Top 25% of 1875 hypotheses

T1 Established

Multi-source converged and validated

T0 Axiom requires manual override only

A Mech. Plausibility 15% 0.80 Top 14%

B+ Evidence Strength 15% 0.70 Top 20%

B+ Novelty 12% 0.75 Top 32%

C+ Feasibility 12% 0.50 Top 65%

A Impact 12% 0.85 Top 30%

B Druggability 10% 0.60 Top 42%

C+ Safety Profile 8% 0.55 Top 47%

C Competition 6% 0.40 Top 92%

B Data Availability 5% 0.65 Top 45%

B Reproducibility 5% 0.60 Top 45%

Evidence

13 supporting | 4 opposing

Citation quality: 85%

Debates

18 sessions B

Avg quality: 0.61

Convergence

0.53 C+ 30 related hypothesis share this target

From Analysis:

Circuit-level neural dynamics in neurodegeneration

Analyze circuit-level changes in neurodegeneration using Allen Institute Neural Dynamics data. Focus on: (1) hippocampal circuit disruption, (2) cortical dynamics alterations, (3) sensory processing changes. Identify circuit-based therapeutic targets connecting genes, proteins, and brain regions to neurodegeneration phenotypes.

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

Locus Coeruleus-Hippocampal Circuit Protection starts from the claim that modulating MAPT within the disease context of neuroscience can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Locus Coeruleus-Hippocampal Circuit Protection starts from the claim that modulating MAPT within the disease context of neuroscience can redirect a disease-relevant process. The original description reads: "## Molecular Mechanism and Rationale The locus coeruleus-hippocampal circuit protection hypothesis centers on the premise that tau pathology, encoded by the MAPT gene, initiates neurodegeneration through a specific anatomical vulnerability pattern. The locus coeruleus, the brain's primary noradrenergic nucleus, exhibits selective susceptibility to tau accumulation in the earliest stages of Alzheimer's disease and related tauopathies. This vulnerability stems from the unique cellular characteristics of locus coeruleus neurons, including their extensive axonal arbor, high metabolic demands, and reduced antioxidant capacity compared to other brainstem nuclei. Mechanistically, hyperphosphorylated tau protein disrupts microtubule stability within locus coeruleus neurons, impairing axonal transport and compromising the delivery of norepinephrine to hippocampal targets. The resulting noradrenergic denervation creates a cascade of downstream effects in the hippocampus, where norepinephrine normally modulates synaptic plasticity, neuroinflammation, and cellular stress responses. Loss of noradrenergic tone diminishes the hippocampus's resilience to subsequent tau pathology, creating a feed-forward cycle of neurodegeneration. The β1 and α2 adrenergic receptors in hippocampal pyramidal neurons and interneurons lose their modulatory input, disrupting theta rhythm generation, long-term potentiation, and memory consolidation processes that depend on intact noradrenergic signaling. ## Preclinical Evidence Animal models of tauopathy demonstrate that selective locus coeruleus lesions accelerate hippocampal tau pathology and memory deficits, supporting the protective role of intact noradrenergic innervation. Transgenic mice expressing human tau mutations show early locus coeruleus dysfunction preceding hippocampal involvement, with corresponding electrophysiological changes in theta-gamma coupling and spatial memory formation. Post-mortem human studies reveal that locus coeruleus tau pathology correlates more strongly with cognitive decline than cortical tau burden in early-stage disease, suggesting this circuit's critical role in maintaining cognitive function. Pharmacological studies using norepinephrine transporter blockers and α2 agonists in tau transgenic models demonstrate partial rescue of hippocampal-dependent memory tasks and preservation of synaptic markers. Optogenetic stimulation of locus coeruleus terminals in the hippocampus similarly restores learning deficits in early-stage tau models, indicating that maintaining noradrenergic function can compensate for developing pathology. ## Therapeutic Strategy The therapeutic approach focuses on multifaceted neuroprotection of the locus coeruleus-hippocampal circuit through several complementary mechanisms. Primary strategies include enhancing locus coeruleus neuronal resilience through mitochondrial support, antioxidant supplementation, and tau aggregation inhibitors specifically targeted to brainstem regions. Noradrenergic replacement therapy using selective norepinephrine reuptake inhibitors or novel noradrenergic modulators could maintain hippocampal function despite ongoing locus coeruleus degeneration. Advanced approaches involve gene therapy targeting MAPT expression specifically in locus coeruleus neurons, utilizing viral vectors with noradrenergic-specific promoters to reduce tau production at the source of pathology spread. Alternatively, enhancing hippocampal noradrenergic receptor sensitivity through positive allosteric modulators could amplify residual noradrenergic signaling, maintaining circuit function with reduced input. ## Biomarkers and Endpoints Key biomarkers include locus coeruleus integrity measured through specialized magnetic resonance imaging sequences sensitive to neuromelanin content, providing a non-invasive assessment of noradrenergic neuron viability. Cerebrospinal fluid norepinephrine metabolites serve as peripheral markers of central noradrenergic function, while hippocampal electrophysiological recordings during cognitive tasks reveal circuit-level functional endpoints. Primary endpoints focus on hippocampal-dependent memory tasks, including spatial navigation, episodic memory formation, and working memory capacity. Electrophysiological measures encompass theta rhythm coherence, gamma oscillation power, and cross-frequency coupling between hippocampal subregions, providing sensitive indices of circuit integrity before gross structural changes occur. ## Potential Challenges Major challenges include the anatomical inaccessibility of the locus coeruleus for direct therapeutic intervention and the difficulty in achieving region-specific drug delivery. The compensation potential of remaining noradrenergic neurons may complicate assessment of therapeutic efficacy, while individual variability in noradrenergic receptor expression affects treatment response predictability. ## Connection to Neurodegeneration This hypothesis reframes neurodegeneration as a circuit-based phenomenon rather than isolated protein pathology, emphasizing how anatomical connectivity patterns determine disease progression. By targeting the earliest vulnerable nodes in the tau propagation network, this approach offers potential disease-modifying effects rather than symptomatic treatment, addressing the fundamental mechanisms driving cognitive decline in tauopathies." Framed more explicitly, the hypothesis centers MAPT within the broader disease setting of neuroscience. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating MAPT or the surrounding pathway space around Tau protein / microtubule-associated pathway can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.70, novelty 0.75, feasibility 0.50, impact 0.85, and mechanistic plausibility 0.80. ## Molecular and Cellular Rationale The nominated target genes are `MAPT` and the pathway label is `Tau protein / microtubule-associated pathway`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neuroscience, the working model should be treated as a circuit of stress propagation. Perturbation of MAPT or Tau protein / microtubule-associated pathway is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Early electrophysiological disintegration of hippocampal neural networks occurs in a locus coeruleus tau-seeding mouse model of Alzheimer's disease, suggesting this pathway is critical for circuit maintenance. Identifier 31285742. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Hippocampal interneurons shape spatial coding alterations in neurological disorders. Identifier 40392508. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. TP53/TAU axis regulates microtubule bundling to control alveolar stem cell-mediated regeneration. Identifier 41642658. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies. Identifier 41804841. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Differential genome-wide association analysis of schizophrenia and post-traumatic stress disorder identifies opposing effects at the MAPT/CRHR1 locus. Identifier 41767305. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 6. Shared genetic architecture between Parkinson's disease and self-reported sleep-related traits implicates the MAPT locus on chromosome 17. Identifier 41822813. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review. Identifier 41931258. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Viral and non-viral cellular therapies for neurodegeneration. Identifier 41585268. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insights. Identifier 41619411. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers in PTSD and Neurological Disorders. Identifier 41828591. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6701`, debate count `3`, citations `14`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 2. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 3. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates MAPT in a model matched to neuroscience. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Locus Coeruleus-Hippocampal Circuit Protection". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting MAPT within the disease frame of neuroscience can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers MAPT within the broader disease setting of neuroscience. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating MAPT or the surrounding pathway space around Tau protein / microtubule-associated pathway can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.70, novelty 0.75, feasibility 0.50, impact 0.85, and mechanistic plausibility 0.80.

Molecular and Cellular Rationale

The nominated target genes are `MAPT` and the pathway label is `Tau protein / microtubule-associated pathway`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
Within neuroscience, the working model should be treated as a circuit of stress propagation. Perturbation of MAPT or Tau protein / microtubule-associated pathway is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Early electrophysiological disintegration of hippocampal neural networks occurs in a locus coeruleus tau-seeding mouse model of Alzheimer's disease, suggesting this pathway is critical for circuit maintenance. Identifier 31285742. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Hippocampal interneurons shape spatial coding alterations in neurological disorders. Identifier 40392508. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

TP53/TAU axis regulates microtubule bundling to control alveolar stem cell-mediated regeneration. Identifier 41642658. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies. Identifier 41804841. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Differential genome-wide association analysis of schizophrenia and post-traumatic stress disorder identifies opposing effects at the MAPT/CRHR1 locus. Identifier 41767305. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Shared genetic architecture between Parkinson's disease and self-reported sleep-related traits implicates the MAPT locus on chromosome 17. Identifier 41822813. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review. Identifier 41931258. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Viral and non-viral cellular therapies for neurodegeneration. Identifier 41585268. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insights. Identifier 41619411. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers in PTSD and Neurological Disorders. Identifier 41828591. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6701`, debate count `3`, citations `14`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates MAPT in a model matched to neuroscience. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Locus Coeruleus-Hippocampal Circuit Protection".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting MAPT within the disease frame of neuroscience can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["MAPT gene
expression"]
    B["Tau protein
production"]
    C["Hyperphosphorylated
tau accumulation"]
    D["Locus coeruleus
neurons"]
    E["Microtubule
destabilization"]
    F["Axonal transport
impairment"]
    G["Norepinephrine
release reduction"]
    H["Hippocampal
noradrenergic
denervation"]
    I["Synaptic plasticity
dysfunction"]
    J["Neuroinflammation
activation"]
    K["Cellular stress
response failure"]
    L["Hippocampal tau
pathology spread"]
    M["Memory and
cognitive decline"]
    N["Noradrenergic
replacement therapy"]
    O["Tau aggregation
inhibitors"]

    A -->|"transcription"| B
    B -->|"pathological
modification"| C
    C -->|"selective
vulnerability"| D
    D -->|"tau toxicity"| E
    E -->|"transport
disruption"| F
    F -->|"neurotransmitter
depletion"| G
    G -->|"circuit
disconnection"| H
    H -->|"loss of
modulation"| I
    H -->|"reduced
anti-inflammatory"| J
    H -->|"impaired
neuroprotection"| K
    I -->|"functional
decline"| M
    J -->|"tissue
damage"| L
    K -->|"vulnerability
increase"| L
    L -->|"progressive
pathology"| M
    N -->|"circuit
restoration"| H
    O -->|"tau
reduction"| C

    classDef normal fill:#4fc3f7
    classDef therapeutic fill:#81c784
    classDef pathology fill:#ef5350
    classDef outcome fill:#ffd54f
    classDef molecular fill:#ce93d8

    class A,B,D,G molecular
    class E,F,I,K normal
    class C,H,J,L pathology
    class M outcome
    class N,O therapeutic

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for MAPT from GTEx v10.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

17 citations 17 with PMID Validation: 85% 13 supporting / 4 opposing

✓ For (13)

No supporting evidence

No opposing evidence

(4) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 6CLIN 7GENE 4EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Early electrophysiological disintegration of hippo…	Supporting	GENE	-	-	-	-	PMID:31285742	-
Hippocampal interneurons shape spatial coding alte…	Supporting	MECH	-	-	-	-	PMID:40392508	-
TP53/TAU axis regulates microtubule bundling to co…	Supporting	MECH	J Clin Invest	-	2026	0.33	PMID:41642658	-
Genetic architecture of plasma pTau217 and related…	Supporting	CLIN	Alzheimers Deme…	-	2026	0.33	PMID:41804841	-
Differential genome-wide association analysis of s…	Supporting	GENE	Front Genet	-	2026	0.33	PMID:41767305	-
Shared genetic architecture between Parkinson'…	Supporting	GENE	Sleep Adv	-	2026	0.33	PMID:41822813	-
Spontaneous tauopathy with parkinsonism in an aged…	Supporting	MECH	Front Aging Neu…	-	2026	0.33	PMID:41695270	-
Progressive Supranuclear Palsy-A Global Review.	Supporting	CLIN	Mov Disord Clin…	-	2026	0.33	PMID:40898879	-
Alzheimer's disease basics: we all should kno…	Supporting	MECH	Neurol Res	-	2026	0.33	PMID:40639927	-
Predicting onset of symptomatic Alzheimer's d…	Supporting	CLIN	Nat Med	-	2026	0.60	PMID:41714746	-
NAD(+) restores proteostasis through splicing-depe…	Supporting	MECH	Autophagy	-	2026	0.49	PMID:41313318	-
A minimally invasive dried blood spot biomarker te…	Supporting	CLIN	Nat Med	-	2026	0.33	PMID:41491101	-
Plasma pTau 217/β-amyloid 1-42 ratio for enhanced …	Supporting	GENE	Brain	-	2026	-	PMID:41562409	-
CRISPR-Cas9 and next-generation gene editing strat…	Opposing	CLIN	Acta Neurol Bel…	-	2026	0.33	PMID:41931258	-
Viral and non-viral cellular therapies for neurode…	Opposing	MECH	Front Med (Laus…	-	2025	0.33	PMID:41585268	-
Experimental and translational models of Alzheimer…	Opposing	CLIN	J Prev Alzheime…	-	2026	0.33	PMID:41619411	-
Astroglial and Neuronal Injury Markers (GFAP, UCHL…	Opposing	CLIN	Int J Mol Sci	-	2026	0.33	PMID:41828591	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 13

Early electrophysiological disintegration of hippocampal neural networks occurs in a locus coeruleus tau-seedi…▼

PMID:31285742

Hippocampal interneurons shape spatial coding alterations in neurological disorders

PMID:40392508

TP53/TAU axis regulates microtubule bundling to control alveolar stem cell-mediated regeneration.

J Clin Invest · 2026 · PMID:41642658 · Q:0.33

Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide associati…▼

Genetic architecture of plasma pTau217 and related biomarkers in Alzheimer's disease via genome-wide association studies.

Alzheimers Dement · 2026 · PMID:41804841 · Q:0.33

Differential genome-wide association analysis of schizophrenia and post-traumatic stress disorder identifies o…▼

Differential genome-wide association analysis of schizophrenia and post-traumatic stress disorder identifies opposing effects at the MAPT/CRHR1 locus.

Front Genet · 2026 · PMID:41767305 · Q:0.33

Shared genetic architecture between Parkinson's disease and self-reported sleep-related traits implicates the …▼

Shared genetic architecture between Parkinson's disease and self-reported sleep-related traits implicates the MAPT locus on chromosome 17.

Sleep Adv · 2026 · PMID:41822813 · Q:0.33

Spontaneous tauopathy with parkinsonism in an aged cynomolgus macaque.

Front Aging Neurosci · 2026 · PMID:41695270 · Q:0.33

Progressive Supranuclear Palsy-A Global Review.

Mov Disord Clin Pract · 2026 · PMID:40898879 · Q:0.33

Alzheimer's disease basics: we all should know.

Neurol Res · 2026 · PMID:40639927 · Q:0.33

Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.

Nat Med · 2026 · PMID:41714746 · Q:0.60

NAD(+) restores proteostasis through splicing-dependent autophagy.

Autophagy · 2026 · PMID:41313318 · Q:0.49

A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology.

Nat Med · 2026 · PMID:41491101 · Q:0.33

Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathol…▼

Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology.

Brain · 2026 · PMID:41562409

✗ Opposing Evidence 4

CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative path…▼

CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review.

Acta Neurol Belg · 2026 · PMID:41931258 · Q:0.33

Viral and non-viral cellular therapies for neurodegeneration.

Front Med (Lausanne) · 2025 · PMID:41585268 · Q:0.33

Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insi…▼

Experimental and translational models of Alzheimer's disease: From neurodegeneration to novel therapeutic insights.

J Prev Alzheimers Dis · 2026 · PMID:41619411 · Q:0.33

Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers…▼

Astroglial and Neuronal Injury Markers (GFAP, UCHL-1, NfL, Tau, S100B) as Diagnostic and Prognostic Biomarkers in PTSD and Neurological Disorders.

Int J Mol Sci · 2026 · PMID:41828591 · Q:0.33

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Hypothesis Debate | 6 rounds | 2026-04-27 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Mechanistic Analysis: Closed-Loop tFUS with 40Hz Gamma Entrainment Targeting PVALB in Early MCI

Critical Evaluation of Mechanistic Rationale

1. Foundational Claim: PV+ Interneurons as Gamma Pacemakers

The hypothesis correctly identifies parvalbumin-positive (PV+) fast-spiking interneurons as critical for gamma oscillation generation in hippocampal CA1. This is well-supported by extensive literature:

Buzsáki & Wang (2012) established the "interneuron network gamma" (ING) mechanism where PV+ cells synchronize through electrical coupling and rebound excitation
**Cardin et a

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Rigorous Skeptic's Critique: tFUS + 40Hz Gamma Entrainment Targeting PVALB in Early MCI

1. Weakest Assumptions

A. Mechanistic Specificity of tFUS → Ion Channel Cascade

Critical flaw: The hypothesis claims tFUS directly activates Nav1.1, Cav2.1, Cav1.3, Piezo1, and TREK-1 to trigger a specific molecular cascade. This assumes:

Mechanical forces from tFUS can selectively activate voltage-gated ion channels (designed for electrical, not mechanical, stimuli)

The downstream CaMKII → AMPA receptor phosphorylation occurs specifically in PV+ interneurons

This cascade is suff

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Translational Feasibility Assessment

Hypothesis: Closed-Loop tFUS with 40Hz Gamma Entrainment Targeting PV+ Interneuron Dysfunction in Early MCI

1. Target Druggability and Accessibility Assessment

Target Identification:

PVALB encodes parvalbumin, a calcium-binding protein that defines a distinct GABAergic interneuron subclass
PVALB itself is not directly druggable—it is a structural protein, not an enzyme or receptor
The actual functional target is PV+ interneuron activity and resulting 40Hz gamma oscillations

Accessibility with Existing Tools:

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Synthesized Assessment: Closed-Loop tFUS with 40Hz Gamma Entrainment for Early MCI

Five-Dimensional Scoring

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Mechanistic Plausibility | 0.82 | The PV+ interneuron → gamma oscillation link is robustly established (Cardin et al., PMID:19339603; Buzsáki & Wang, 2012). However, the hypothesis overstates mechanistic precision by claiming direct activation of specific voltage-gated channels (Nav1.1, Cav2.1, Cav1.3) via tFUS. Evidence for mechanosensitive activation of these channels remains indirect. |
| **Evidence Str

Price History

7d Trend

↘

Falling

7d Momentum

▼ 5.3%

Volatility

Low

0.0170

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
⚖	Recalibrated	$0.486	▼ 0.9%	market_dynamics	2026-04-13 03:33
📄	New Evidence	$0.491	▲ 2.4%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.479	▲ 2.9%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.466	▼ 0.3%		2026-04-12 18:34
⚖	Recalibrated	$0.467	▼ 0.3%		2026-04-12 10:15
⚖	Recalibrated	$0.469	▼ 1.1%		2026-04-10 15:58
⚖	Recalibrated	$0.474	▼ 5.2%		2026-04-10 15:53
📄	New Evidence	$0.500	▼ 8.2%	evidence_update	2026-04-09 01:50
📄	New Evidence	$0.545	▲ 15.9%	evidence_update	2026-04-09 01:50
⚖	Recalibrated	$0.470	▼ 0.8%		2026-04-08 22:18
⚖	Recalibrated	$0.474	▼ 26.1%		2026-04-08 18:39
💬	Debate Round	$0.641	▲ 4.4%	market_dynamics	2026-04-05 00:40
📄	New Evidence	$0.614	▲ 0.5%	market_dynamics	2026-04-05 00:05
📊	Score Update	$0.611	▼ 3.0%	market_dynamics	2026-04-04 22:12
📄	New Evidence	$0.629	▲ 23.6%	market_dynamics	2026-04-04 21:44

Clinical Trials (5) Relevance: 65%

0
Active

0
Completed

356
Total Enrolled

EARLY_PHASE1
Highest Phase

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients PHASE2

COMPLETED · NCT04388254 · Cassava Sciences, Inc.

220 enrolled · 2020-03-24 · → 2023-11-09

Alzheimer Disease

Simufilam 100 mg oral tablet Placebo

Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain EARLY_PHASE1

COMPLETED · NCT03080051 · Molecular NeuroImaging

6 enrolled · 2016-08 · → 2017-03-06

Progressive Supranuclear Palsy Alzheimer Disease Healthy Volunteers

[18F]MNI-952 [18F]Florbetapir

Understanding Cerebral Blood Flow Dynamics for Alzheimer's Disease Prevention Through Exercise NA

COMPLETED · NCT06584656 · Universidad de Granada

20 enrolled · 2024-09-25 · → 2025-01-02

Healthy Aging Cognitive Function 1, Social Cerebrovascular Circulation

Aerobic exercise condition Resistance exercise condition

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum PHASE2

TERMINATED · NCT02406027 · Janssen Research & Development, LLC

90 enrolled · 2015-07-02 · → 2018-06-28

Alzheimer Disease

JNJ-54861911, 10 mg JNJ-54861911, 25 mg Placebo

Mycose AdminiStration for HealIng Alzheimer NEuropathy (MASHIANE) PHASE1

UNKNOWN · NCT04663854 · Mashhad University of Medical Sciences

20 enrolled · 2020-08-20 · → 2022-03-20

Alzheimer Disease

Trehalose

📚 Cited Papers (32)

Viral and non-viral cellular therapies for neurodegeneration.

Frontiers in medicine (2025) · PMID:41585268

4 figures

Figure 1

No caption available

pmc_api

Figure 1

A schematic diagram of major neurodegenerative disorders and their mechanisms in pathophysiology. The diagram shows Alzheimer's, Parkinson's, Huntington's, and Amyotrophic lateral ...

pmc_api

Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology.

Brain (2026) · PMID:41562409

3 figures

Figure 1

Discriminatory performance of plasma pTau217 and the pTau217/Aβ 1–42 ratio for prediction of amyloid PET + CSF positivity . Receiver operating characteristic (ROC) curves for plas...

pmc_api

Figure 2

Distributional validation and parametric estimation of diagnostic performance for plasma pTau217. Quantile–quantile plots of plasma pTau217 values in amyloid-positive ( A ) and am...

pmc_api

CRISPR-Cas9 and next-generation gene editing strategies for therapeutic intervention of neurodegenerative pathways in Alzheimer's disease: a state-of-the-art review.

Acta Neurol Belg (2026) · PMID:41931258

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Alzheimer's disease basics: we all should know.

Neurological research (2026) · PMID:40639927

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Early Electrophysiological Disintegration of Hippocampal Neural Networks in a Novel Locus Coeruleus Tau-Seeding Mouse Model of Alzheimer's Disease.

Neural plasticity (2020) · PMID:31285742

No extracted figures yet

Hippocampal Interneurons Shape Spatial Coding Alterations in Neurological Disorders.

Molecular neurobiology (2025) · PMID:40392508

No extracted figures yet

Alzheimer's disease basics: we all should know.

Neurological research (2026) · PMID:40639927

No extracted figures yet

Progressive Supranuclear Palsy-A Global Review.

Movement disorders clinical practice (2026) · PMID:40898879

No extracted figures yet

NAD+ restores proteostasis through splicing-dependent autophagy.

Autophagy (2026) · PMID:41313318

No extracted figures yet

A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology.

Nat Med (2026) · PMID:41491101

No extracted figures yet

Plasma pTau 217/β-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology.

Brain (2026) · PMID:41562409

No extracted figures yet

Viral and non-viral cellular therapies for neurodegeneration.

Frontiers in medicine (2025) · PMID:41585268

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Circuit-level neural dynamics in neurodegeneration — Analysis Notebook

CI-generated notebook stub for analysis SDA-2026-04-03-26abc5e5f9f2. Analyze circuit-level changes in neurodegeneration using Allen Institute Neural Dynamics data. Focus on: (1) hippocampal circuit di …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

Variants (3)

mutate Cholinergic Basal Forebrain-Hippocampal Circuit Protection

mutate Glymphatic-Mediated Tau Clearance Dysfunction

crossover Dual-Circuit Tau Vulnerability Cascade

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score

0.70

43.4th percentile (776 hypotheses)

Tokens Used

9,494

KG Edges Generated

1,929

Citations Produced

Cost Ratios

Cost per KG Edge

88.73 tokens

Lower is better (baseline: 2000)

Cost per Citation

558.47 tokens

Lower is better (baseline: 1000)

Cost per Score Point

15312.90 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.070

10% weight of efficiency score

Adjusted Composite

0.738

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-16T20:00	$0.490	0.510

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for MAPT.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for MAPT →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (130)

40Hz gamma entrainment APOE APOE4 APP AQP4 Alzheimer's disease Alzheimer's disease pathology BDNF CA1 CA3 CAMK2A CDK5 CHAT CSF1R CaMKII CaMKII_protein Closed-loop tACS EC layer II SST interneurons Entorhinal cortex layer II GABAergic interneuron networks

Dependency Graph (0 upstream, 6 downstream)

Depended On By

Cholinergic Basal Forebrain-Hippocampal Circuit Protectionrefines (0.5)Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectionrefines (0.5)Dual-Circuit Tau Vulnerability Cascaderefines (0.5)Glymphatic-Mediated Tau Clearance Dysfunctionrefines (0.5)Glymphatic-Cholinergic Tau Clearance Cascaderefines (0.5)Dual-Circuit Tau Vulnerability Cascade with Glial-Mediated Amplificationrefines (0.5)

Linked Experiments (9)

Related Hypotheses

Glymphatic-Mediated Tau Clearance Dysfunction

Score: 0.865 | neuroscience

Dual-Circuit Tau Vulnerability Cascade

Score: 0.774 | neuroscience

Cholinergic Basal Forebrain-Hippocampal Circuit Protection

Score: 0.760 | neuroscience

Repeat-domain exposure defines seed-competent tau conformers

Score: 0.760 | neurodegeneration

Dopaminergic Ventral Tegmental-Hippocampal Circuit Protection

Score: 0.751 | neuroscience

Estimated Development

Estimated Cost

Timeline

5.5 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

IF locus coeruleus (LC) noradrenergic neurons are selectively inhibited using chemogenetic (hM4Di-DREADD) approach in Tau P301S transgenic mice at 3 months of age (pre-symptomatic stage), THEN hippocampal tau phosphorylation at Ser396 (assessed by ELISA) will increase by at least 40% compared to vehicle-treated Tau P301S controls within 12 weeks post-intervention.

pending conf: 0.72

Expected outcome: Hippocampal tau phosphorylation at Ser396 increases by ≥40% in LC-inhibited group relative to controls

Falsified by: If hippocampal tau phosphorylation does not increase significantly (p>0.05, Mann-Whitney U test) in the LC-inhibited group compared to controls, the hypothesis that LC-mediated noradrenergic signaling protects against hippocampal tau pathology is falsified.

Method: Tau P301S transgenic mice (PS19 line, n=20 per group) receiving AAV9-hSyn-hM4Di-mCherry bilateral LC infusion, with CNO (1 mg/kg, i.p.) administration 3x/week from 3-6 months of age. Control groups: Tau P301S with AAV9-hSyn-mCherry (no hM4Di), and wild-type C57BL/6 with hM4Di. Outcome measured at 6 months via ELISA (AT270 and PHF1 antibodies) and AT8 immunostaining.

IF atomoxetine (NET blocker, 3 mg/kg/day, osmotic minipump) is administered to Tau P301L transgenic mice starting at 4 months of age for 8 weeks, THEN performance on the Morris water maze (spatial probe trial) will improve by ≥25% (reduced latency to platform) and hippocampal norepinephrine levels will increase by ≥60% (HPLC) compared to saline-treated Tau P301L littermates.

pending conf: 0.65

Expected outcome: Morris water maze latency reduced by ≥25% and hippocampal NE increased by ≥60% in atomoxetine-treated mice

Falsified by: If atomoxetine treatment fails to produce significant improvement in spatial memory (p>0.05, two-way ANOVA with repeated measures) AND fails to increase hippocampal NE by ≥60% compared to vehicle controls, the hypothesis that enhancing noradrenergic tone protects hippocampal function in tauopathy is falsified.

Method: Tau P301L (rTau) transgenic mice (n=25 per group, balanced by sex), randomized to atomoxetine vs. saline, implanted with Alzet osmotic minipumps at 4 months. Behavioral testing (Morris water maze, Y-maze spontaneous alternation) conducted weeks 6-8. Neurochemical analysis (HPLC-EC) and tau biochemistry (Sarkosyl-insoluble fraction, Western blot) performed at 6 months. Cohort replication in independent facility.

Knowledge Subgraph (138 edges)

▸ Show 10 more

PVALB→Alzheimer's diseaseSST→alzheimer_s_diseasePVALB→alzheimer_s_diseaseBDNF→alzheimer_s_diseasePVALB/SST→neuroscienceSST interneurons→Entorhinal cortex layer IIGamma oscillation disruption→Alzheimer's diseaseamyloid accumulation→PV+ interneuron dysfunctionamyloid accumulation→PV+ interneuronsSST→Alzheimer's disease

biomarker for (1)

gamma collapse→early MCI

catalyzes (1)

choline_acetyltransferase→cholinergic_signaling

causal extracted (2)

sess_ext_h-var-58e76ac310_20260428_050154→processedsess_ext_h-var-3b982ec3d2_20260428_045746→processed

causes (8)

tau pathology→SST interneuron dysfunctionSST interneuron dysfunction→accelerated tau propagationSST interneuron dysfunction→gamma desynchronizationoptogenetic gamma stimulation→tau pathology reductionTau pathology→SST interneuron dysfunction

▸ Show 3 more

Tau pathology→Tau propagationPV+ interneuron dysfunction→gamma collapsegamma collapse→hippocampal-cortical disconnect

causes (CaMKII enhancement promotes dendrite ramification ) (1)

CaMKII→dendrite ramification

causes (CaMKII-dependent process that promotes spine gener) (1)

CaMKII→spine generation

causes (NMDA receptors mediate synaptic depression in amyl) (1)

NMDA receptors→synaptic depression

causes (VIP interneuron-mediated disinhibition allows pyra) (1)

VIP interneuron stimulation→pyramidal cell disinhibition

causes (loss of natural sensory input leads to degeneratio) (1)

natural sensory input loss→cholinergic circuit degeneration

causes (optogenetic activation selectively restores gamma ) (1)

optogenetic activation of PV interneurons→gamma oscillation restoration

causes (optogenetic activation selectively restores theta ) (1)

optogenetic activation of SST interneurons→theta oscillation restoration

causes (selective modulation of GluN2B-containing NMDA rec) (1)

GluN2B modulation→thalamocortical synchronization

causes (selective noradrenaline depletion exacerbates syna) (1)

noradrenaline depletion→synaptic deficits

causes (specifically disrupt parvalbumin-positive interneu) (1)

amyloid-β oligomers→PV interneurons

causes (specifically disrupt somatostatin-positive interne) (1)

amyloid-β oligomers→SST interneurons

causes (tau pathology spreads from locus coeruleus to hipp) (1)

tau pathology→hippocampal circuit dysfunction

co associated with (19)

BDNF→SSTCAMK2A→CHATCAMK2A→VIPCAMK2A→GRIN2BCHAT→VIP

▸ Show 14 more

CHAT→GRIN2BCAMK2A→MAPTCHAT→MAPTMAPT→VIPGRIN2B→MAPTBDNF→PVALBGRIN2B→VIPBDNF→CA3BDNF→CA1CAMK2A→PVALB/SSTCHAT→PVALB/SSTGRIN2B→PVALB/SSTMAPT→PVALB/SSTPVALB/SST→VIP

co discussed (14)

RAB5→TREM2RAB7→TREM2APP→GAD1GAD1→PSEN1BDNF→PSD95

▸ Show 9 more

APOE4→BDNFBDNF→CSF1RBDNF→TREM2HDAC→PSD95APP→PSD95AQP4→MAPTAPOE→TFEBCDK5→MAPKAQP4→TREM2

disrupts (1)

MAPT→hippocampal_circuit

dysfunction causes (1)

thalamocortical_circuit→cognitive_impairment

encodes (4)

CHAT→choline_acetyltransferaseGRIN2B→GluN2B_receptorMAPT→tau_proteinCAMK2A→CaMKII_protein

enhances (2)

gamma oscillations at 40Hz→glymphatic clearancegamma oscillations (40Hz)→glymphatic clearance

expressed in (3)

VIP→VIP_interneuronsPVALB→PV_interneuronsSST→SST_interneurons

generates (4)

PV_interneurons→gamma_oscillationsSST_interneurons→theta_oscillationsPVALB→gamma_oscillationSST→theta_oscillation

implicated in (7)

PVALB→neurodegenerationh-cd60e2ec→neuroscienceh-f8316acf→neuroscienceh-23b94ed8→neuroscienceh-62c78d8b→neuroscience

▸ Show 2 more

h-a635d4e5→neuroscienceh-7110565d→neuroscience

inhibits (1)

tACS→EC layer II SST interneurons

investigated in (4)

diseases-psp→h-var-6612521a02diseases-corticobasal-syndrome→h-var-9c0368bb70diseases-ftd→h-var-3b982ec3d2diseases-vascular-cognitive-impairment→h-var-6612521a02

involved in (3)

SST→gabaergic_interneuron_networksPVALB→prefrontal_inhibitory_circuitsBDNF→hippocampal_neurogenesis_and_synaptic_plasticity

modulates (12)

VIP_interneurons→default_mode_networkGluN2B_receptor→thalamocortical_circuitGRIN2B→thalamocortical_synchronygamma-frequency stimulation→tau pathologyGamma frequency stimulation→Alzheimer's disease pathology

▸ Show 7 more

Optogenetics→SST interneuron modulationClosed-loop tACS→Gamma entrainmentPV+ interneuron activity→excitatory transmissionclosed-loop tFUS→PV+ interneuron activitygamma oscillations (40Hz)→microglial phagocytosisgamma oscillations (40Hz)→excitatory transmissiontranscranial focused ultrasound (tFUS)→deep brain structures

participates in (2)

SST→GABAergic interneuron networksPVALB→Prefrontal inhibitory circuits

promotes (1)

CaMKII_protein→synaptic_plasticity

propagates through (1)

tau_protein→locus_coeruleus_hippocampus_pathway

regulates (5)

SST→gamma_oscillationSST interneurons→gamma oscillationsSST interneurons→Gamma oscillationsgamma oscillations (40Hz)→hippocampal-cortical connectivityPVALB→PV+ interneurons

studied in (3)

SST→neurosciencePVALB→neuroscienceBDNF→neuroscience

targets (2)

h-a635d4e5→VIPBDNF→Alzheimer's disease

therapeutic target (2)

SST→Alzheimer's diseasePVALB→Alzheimer's disease

therapeutic target for (2)

40Hz gamma entrainment→early MCIPV+ interneuron activity→Alzheimer's disease

Mechanism Pathway for MAPT

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    MAPT["MAPT"] -->|disrupts| hippocampal_circuit["hippocampal_circuit"]
    MAPT_1["MAPT"] -->|associated with| neuroscience["neuroscience"]
    MAPT_2["MAPT"] -->|encodes| tau_protein["tau_protein"]
    CAMK2A["CAMK2A"] -->|co associated with| MAPT_3["MAPT"]
    CHAT["CHAT"] -->|co associated with| MAPT_4["MAPT"]
    MAPT_5["MAPT"] -->|co associated with| VIP["VIP"]
    GRIN2B["GRIN2B"] -->|co associated with| MAPT_6["MAPT"]
    MAPT_7["MAPT"] -->|co associated with| PVALB_SST["PVALB/SST"]
    AQP4["AQP4"] -->|co discussed| MAPT_8["MAPT"]
    style MAPT fill:#ce93d8,stroke:#333,color:#000
    style hippocampal_circuit fill:#81c784,stroke:#333,color:#000
    style MAPT_1 fill:#ce93d8,stroke:#333,color:#000
    style neuroscience fill:#ef5350,stroke:#333,color:#000
    style MAPT_2 fill:#ce93d8,stroke:#333,color:#000
    style tau_protein fill:#4fc3f7,stroke:#333,color:#000
    style CAMK2A fill:#ce93d8,stroke:#333,color:#000
    style MAPT_3 fill:#ce93d8,stroke:#333,color:#000
    style CHAT fill:#ce93d8,stroke:#333,color:#000
    style MAPT_4 fill:#ce93d8,stroke:#333,color:#000
    style MAPT_5 fill:#ce93d8,stroke:#333,color:#000
    style VIP fill:#ce93d8,stroke:#333,color:#000
    style GRIN2B fill:#ce93d8,stroke:#333,color:#000
    style MAPT_6 fill:#ce93d8,stroke:#333,color:#000
    style MAPT_7 fill:#ce93d8,stroke:#333,color:#000
    style PVALB_SST fill:#ce93d8,stroke:#333,color:#000
    style AQP4 fill:#ce93d8,stroke:#333,color:#000
    style MAPT_8 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 MAPT — PDB 5O3L Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Circuit-level neural dynamics in neurodegeneration

neuroscience | 2026-04-03 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (5)

GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Clearance

Score: 0.96 · GRIN2B

Closed-loop transcranial focused ultrasound targeting EC-II SST intern

Score: 0.96 · SST

Closed-loop optogenetic targeting PV interneurons to restore theta-gam

Score: 0.95 · PVALB

Closed-loop transcranial focused ultrasound to restore hippocampal gam

Score: 0.91 · CCK

Gamma entrainment therapy to restore hippocampal-cortical synchrony

Score: 0.90 · SST

→ View all analysis hypotheses

Locus Coeruleus-Hippocampal Circuit Protection

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

GTEx v10 Brain Expression

Dimension Scores

✓ Supporting Evidence 13

✗ Opposing Evidence 4

Mechanistic Analysis: Closed-Loop tFUS with 40Hz Gamma Entrainment Targeting PVALB in Early MCI

Critical Evaluation of Mechanistic Rationale

1. Foundational Claim: PV+ Interneurons as Gamma Pacemakers

Rigorous Skeptic's Critique: tFUS + 40Hz Gamma Entrainment Targeting PVALB in Early MCI

1. Weakest Assumptions

A. Mechanistic Specificity of tFUS → Ion Channel Cascade

Translational Feasibility Assessment

Hypothesis: Closed-Loop tFUS with 40Hz Gamma Entrainment Targeting PV+ Interneuron Dysfunction in Early MCI

1. Target Druggability and Accessibility Assessment

Synthesized Assessment: Closed-Loop tFUS with 40Hz Gamma Entrainment for Early MCI

Five-Dimensional Scoring

Price History

Clinical Trials (5) Relevance: 65%

📚 Cited Papers (32)

📅 Citation Freshness Audit

📙 Related Wiki Pages (0)

📓 Linked Notebooks (1)

⚔ Arena Performance

Variants (3)

🔄 Related Hypotheses

Same Analysis (5)

🧬 Same Target Gene / Disease (30)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Efficiency Price Signals

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

KG Entities (130)

Dependency Graph (0 upstream, 6 downstream)

Linked Experiments (9)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (138 edges)

accelerates (1)

activates (5)

associated with (15)

biomarker for (1)

catalyzes (1)

causal extracted (2)

causes (8)

causes (CaMKII enhancement promotes dendrite ramification ) (1)

causes (CaMKII-dependent process that promotes spine gener) (1)

causes (NMDA receptors mediate synaptic depression in amyl) (1)

causes (VIP interneuron-mediated disinhibition allows pyra) (1)

causes (loss of natural sensory input leads to degeneratio) (1)

causes (optogenetic activation selectively restores gamma ) (1)

causes (optogenetic activation selectively restores theta ) (1)

causes (selective modulation of GluN2B-containing NMDA rec) (1)

causes (selective noradrenaline depletion exacerbates syna) (1)

causes (specifically disrupt parvalbumin-positive interneu) (1)

causes (specifically disrupt somatostatin-positive interne) (1)

causes (tau pathology spreads from locus coeruleus to hipp) (1)

co associated with (19)

co discussed (14)

disrupts (1)

dysfunction causes (1)

encodes (4)

enhances (2)

expressed in (3)

generates (4)

implicated in (7)